Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR-ZFN
- Development stage
- Unknown
- Lead developer
- Sangamo Therapeutics
- Modality
- Zinc Finger Nucleases → Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
GR-ZFN is an ex vivo gene-editing therapeutic agent consisting of a pair of zinc finger nucleases (ZFNs) designed to specifically target and disrupt the *NR3C1* gene, which encodes the human glucocorticoid receptor (GR). Developed by Sangamo Therapeutics in collaboration with the City of Hope National Medical Center, this technology is used to engineer T cells—such as CMV-specific T cells or CAR-T cells—to be resistant to the immunosuppressive effects of glucocorticoids like dexamethasone. By knocking out the GR, these modified T cells can maintain their cytotoxic anti-tumor activity even when patients are treated with steroids to manage inflammatory side effects or cerebral edema. The therapy has been evaluated in Phase 1 clinical trials for patients with recurrent glioblastoma multiforme.
- Other names
- Glucocorticoid receptor-specific zinc finger nucleaseNR3C1-ZFNNR-3C1-ZFNNR 3C1-ZFN
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on GR-ZFN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR-ZFN.